Hypoglycemic activity of a series of α-alkylthio and α-alkoxy carboxylic acids related to ciglitazone

Journal of Medicinal Chemistry

Volumn 39, Issue 20, 1996, Pages 3897-3907

  Hulin, Bernard ^a   Newton, Linda S ^a   Lewis, Diana M ^a   Genereux, Paul E ^a   Gibbs, E Michael ^a   Clark, David A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BENZOPYRAN DERIVATIVE; CARBOXYLIC ACID; CIGLITAZONE; HYDROXYUREA; INSULIN; SULFONYLUREA;

ARTICLE; ATHEROSCLEROSIS; DRUG ACTIVITY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; RISK ASSESSMENT; STEREOCHEMISTRY;

3T3 CELLS; ADIPOCYTES; ANIMALS; BENZOFURANS; CARBOXYLIC ACIDS; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; MICE; MICE, MUTANT STRAINS; MICE, OBESE; MOLECULAR STRUCTURE; OXAZOLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0029793540     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960230h     Document Type: Article

References (51)

1. (a) Rushforth, N. B.; Miller, N.; Bennett, P. H. Fasting and Two-hour Post-Load Glucose Levels for the Diagnosis of Diabetes. The Relationship between Glucose Levels and Complications of Diabetes in the Pima Indians. Diabetologia 1979, 16, 373-379.
2. (b) Knuiman, M. W.; Welborn, T. A.; Mc Cann, V. J.; Stanton, K. G.; Constable, I. J. Prevalence of Diabetic Complications in Relation to Risk Factors. Diabetes 1986, 35, 1332-1339.
3. (c) Feldt-Rasmussen, B.; Mathiesen, E.; Deckert, T. Effect of Two Years of Strict Metabolic Control on Progression of Incipient Nephropathy in Insulin-Dependent Diabetes. Lancet 1986, No. 2, 1300-1304.
4. (d) Dahl-Jorgensen, K.; Brinchmann-Hansen, O.; Hanssen, K. F.; Ganes, T.; Kierulf, P.; Smeland, E.; Sandvik, L.; Aagenaes, O. Effect of Near-Normoglycemia for Two Years on Progression of Early Diabetic Retinopathy, Nephropathy, and Neuropathy: the Oslo Study. Br. Med. J. 1986, 293, 1195-1199.
5. (e) Pirart, J. Diabetes Mellitus and its Degenerative Complications. A Prospective Study of 4,400 Patients Observed between 1947 and 1973. Diabetes Care 1978, 1, 168-188.
6. (f) Pirart, J. Diabetes Mellitus and its Degenerative Complications. A Prospective Study of 4,400 Patients Observed between 1947 and 1973. Diabetes Care 1978, 1, 252-263.
7. Williams, G. Management of Non-Insulin-Dependent Diabetes Mellitus. Lancet 1994, 95-100.
8. (a) The Diabetes Control and Complications Trial Research Group. The Effect of Intensive treatment on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977-986.
9. (b) Eastman, R. C.; Siebert, C. W.; Harris, M.; Gorden, P. Implications of the Diabetes Control and Complications Trial. J. Clin. Endoc. Metab. 1993, 77, 1105-1107.
10. (c) American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes 1993, 42, 1555-1558.
11. (a) Steiner, K. E.; Lien, E. L. Hypoglycaemic Agents Which Do Not Release Insulin. Progr. Med. Chem. 1987, 24, 209-248.
12. (b) New Antidiabetic Drugs; Bailey, C. J., Flatt, P. R., Eds.; Smith, Gordon & Co.: London, 1990.
13. (c) Hulin, B. New Hypoglycaemic Agents. Progr. Med. Chem. 1994, 31, 1-58.
14. Hulin, B.; McCarthy, P. A.; Gibbs, E. M. The Glitazone Family of Antidiabetic Agents. Curr. Pharm. Des. 1996, 2, 85-102.
15. (a) Sohda, T.; Mizuno, K.; Imamiya, E.; Sugiyama, Y; Fujita, T.; Kawamatsu, Y. Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878) and Its Derivatives. Chem. Pharm. Bull. 1982, 30, 3580-3600.
16. (b) Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamatsu, Y.; Iwatsuka, H.; Suzuoki, Z. Reduction of Insulin Resistance in Obese and Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent. Diabetes 1983, 32, 804-810.
17. (c) Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, A. R. Ciglitazone, A New Hypoglycemic Agent. I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats. Diabetes 1983, 32, 830-838.
18. Recent references on thiazolidinediones: (a) Cawthorne, M. A.; Lister, C. A.; Holder, J. C.; Kirkham, D. M.; Young, P. W.; Cantello, B. C.; Hindley, R. M.; Smith, S. A. Anti-hyperglycaemic Efficacy of BRL 49653, a highly potent Thiazolidinedione, in Animal Models of Non-insulin Dependent Diabetes. Diabetes 1993, 42 (Suppl. 1), 204A. (b) Yen, T.; Bue-Valleskey, J.; Burkhart, D.; Dininger, N.; Gill, A.; Gold, G.; Johnson, T.; Myers, S.; Shaw, W.; Short, W.; Tinsley, F.; Williams, G.; Williams, V.; Yakubu-Madus, F. The Efficacy and Adverse Effects of a Potent Insulin Sensitivity Enhancer: LY282449 (Tanabe-174). Diabetologia 1993, 36 (Suppl. 1), A182. (c) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[o-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985. (d) de Nanteuil, G.; Herve, Y.; Duhault, J.; Espinal, J.; Boulanger, M.; Ravel, D. Euglycaemic and Biological Activities of Novel Thiazolidine-2,4-dione Derivatives Arzneim.-Forsch./Drug Res. 1995, 45, 1176-1181.
19. Recent references on thiazolidinediones: (a) Cawthorne, M. A.; Lister, C. A.; Holder, J. C.; Kirkham, D. M.; Young, P. W.; Cantello, B. C.; Hindley, R. M.; Smith, S. A. Anti-hyperglycaemic Efficacy of BRL 49653, a highly potent Thiazolidinedione, in Animal Models of Non-insulin Dependent Diabetes. Diabetes 1993, 42 (Suppl. 1), 204A. (b) Yen, T.; Bue-Valleskey, J.; Burkhart, D.; Dininger, N.; Gill, A.; Gold, G.; Johnson, T.; Myers, S.; Shaw, W.; Short, W.; Tinsley, F.; Williams, G.; Williams, V.; Yakubu-Madus, F. The Efficacy and Adverse Effects of a Potent Insulin Sensitivity Enhancer: LY282449 (Tanabe-174). Diabetologia 1993, 36 (Suppl. 1), A182. (c) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[o-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985. (d) de Nanteuil, G.; Herve, Y.; Duhault, J.; Espinal, J.; Boulanger, M.; Ravel, D. Euglycaemic and Biological Activities of Novel Thiazolidine-2,4-dione Derivatives Arzneim.-Forsch./Drug Res. 1995, 45, 1176-1181.
20. Recent references on thiazolidinediones: (a) Cawthorne, M. A.; Lister, C. A.; Holder, J. C.; Kirkham, D. M.; Young, P. W.; Cantello, B. C.; Hindley, R. M.; Smith, S. A. Anti-hyperglycaemic Efficacy of BRL 49653, a highly potent Thiazolidinedione, in Animal Models of Non-insulin Dependent Diabetes. Diabetes 1993, 42 (Suppl. 1), 204A. (b) Yen, T.; Bue-Valleskey, J.; Burkhart, D.; Dininger, N.; Gill, A.; Gold, G.; Johnson, T.; Myers, S.; Shaw, W.; Short, W.; Tinsley, F.; Williams, G.; Williams, V.; Yakubu-Madus, F. The Efficacy and Adverse Effects of a Potent Insulin Sensitivity Enhancer: LY282449 (Tanabe-174). Diabetologia 1993, 36 (Suppl. 1), A182. (c) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[o-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985. (d) de Nanteuil, G.; Herve, Y.; Duhault, J.; Espinal, J.; Boulanger, M.; Ravel, D. Euglycaemic and Biological Activities of Novel Thiazolidine-2,4-dione Derivatives Arzneim.-Forsch./Drug Res. 1995, 45, 1176-1181.
21. Recent references on thiazolidinediones: (a) Cawthorne, M. A.; Lister, C. A.; Holder, J. C.; Kirkham, D. M.; Young, P. W.; Cantello, B. C.; Hindley, R. M.; Smith, S. A. Anti-hyperglycaemic Efficacy of BRL 49653, a highly potent Thiazolidinedione, in Animal Models of Non-insulin Dependent Diabetes. Diabetes 1993, 42 (Suppl. 1), 204A. (b) Yen, T.; Bue-Valleskey, J.; Burkhart, D.; Dininger, N.; Gill, A.; Gold, G.; Johnson, T.; Myers, S.; Shaw, W.; Short, W.; Tinsley, F.; Williams, G.; Williams, V.; Yakubu-Madus, F. The Efficacy and Adverse Effects of a Potent Insulin Sensitivity Enhancer: LY282449 (Tanabe-174). Diabetologia 1993, 36 (Suppl. 1), A182. (c) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[o-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985. (d) de Nanteuil, G.; Herve, Y.; Duhault, J.; Espinal, J.; Boulanger, M.; Ravel, D. Euglycaemic and Biological Activities of Novel Thiazolidine-2,4-dione Derivatives Arzneim.-Forsch./Drug Res. 1995, 45, 1176-1181.
22. Kumar, S.; Boulton, A. J. M.; Beck-Nielsen, H.; Berthezene, F.; Muggeo, M.; Persson, B.; Spinas, G. A.; Donoghue, S.; Lettis, S.; Stewart-Long, P., for the Troglitazone Group. Troglitazone, an Insulin Action Enhancer, Improves Metabolic Control in NIDDM Patients. Diabetologia 1996, 30, 701-709.
23. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on Antidiabetic Agents. 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents. J. Med. Chem. 1992, 35, 2617-2626.
24. Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel Thiazolidinediones as Potent Euglycemic Agents. J. Med. Chem. 1992, 35, 1853-1864.
25. (a) Dow, R. L.; Bechle, B. M.; Chou, T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-diones as Potent Hypoglycemic Agents. J. Med. Chem. 1991, 34, 1538-1544.
26. (b) Gibbs, E. M.; Genereux, P. E.; Dow, R. L. The Benzyloxazolidinedione, CP-92768, is a Potent Antidiabetic Agent In Vivo an In Vitro. Diabetes 1993, 42 (Suppl. 1), 207A.
27. Goldstein, S. W.; McDermott, R. E.; Gibbs, E. M.; Stevenson, R. W. Hydroxyurea Derivatives as Hypoglycemic Agents. J. Med. Chem. 1993, 36, 2238-2240.
28. Other heterocyclic replacements have been used; however, it is not clear whether the compounds are mechanistically equivalent to ciglitazone: (a) Ellingboe, J. W.; Alessi, T. R.; Dolak, T. M.; Nguyen, T. T.; Tomer, J. D.; Guzzo, F.; Bagli, J. F.; McCaleb, M. L. Antihyperglycemic Activity of Novel Substituted 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1992, 35, 1176-1183. (b) Ellingboe, J. W.; Lombardo, L. J.; Alessi, T. R.; Nguyen, T. T.; Guzzo, F.; Guinosso, C. J.; Bullington, J.; Browne, E. N. C.; Bagli, J. F.; Wrenn, J.; Steiner, K.; McCaleb, M. L. Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1993, 36, 2485-2493. (c) Kees, K. L. U.S. Pat. 5,183,825. (d) Kees, K. L. U.S. Pat. 5,264,451. (e) Kees, K. L. U.S. Pat. 5,274,111.
29. Other heterocyclic replacements have been used; however, it is not clear whether the compounds are mechanistically equivalent to ciglitazone: (a) Ellingboe, J. W.; Alessi, T. R.; Dolak, T. M.; Nguyen, T. T.; Tomer, J. D.; Guzzo, F.; Bagli, J. F.; McCaleb, M. L. Antihyperglycemic Activity of Novel Substituted 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1992, 35, 1176-1183. (b) Ellingboe, J. W.; Lombardo, L. J.; Alessi, T. R.; Nguyen, T. T.; Guzzo, F.; Guinosso, C. J.; Bullington, J.; Browne, E. N. C.; Bagli, J. F.; Wrenn, J.; Steiner, K.; McCaleb, M. L. Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1993, 36, 2485-2493. (c) Kees, K. L. U.S. Pat. 5,183,825. (d) Kees, K. L. U.S. Pat. 5,264,451. (e) Kees, K. L. U.S. Pat. 5,274,111.
30. Other heterocyclic replacements have been used; however, it is not clear whether the compounds are mechanistically equivalent to ciglitazone: (a) Ellingboe, J. W.; Alessi, T. R.; Dolak, T. M.; Nguyen, T. T.; Tomer, J. D.; Guzzo, F.; Bagli, J. F.; McCaleb, M. L. Antihyperglycemic Activity of Novel Substituted 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1992, 35, 1176-1183. (b) Ellingboe, J. W.; Lombardo, L. J.; Alessi, T. R.; Nguyen, T. T.; Guzzo, F.; Guinosso, C. J.; Bullington, J.; Browne, E. N. C.; Bagli, J. F.; Wrenn, J.; Steiner, K.; McCaleb, M. L. Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1993, 36, 2485-2493. (c) Kees, K. L. U.S. Pat. 5,183,825. (d) Kees, K. L. U.S. Pat. 5,264,451. (e) Kees, K. L. U.S. Pat. 5,274,111.
31. Other heterocyclic replacements have been used; however, it is not clear whether the compounds are mechanistically equivalent to ciglitazone: (a) Ellingboe, J. W.; Alessi, T. R.; Dolak, T. M.; Nguyen, T. T.; Tomer, J. D.; Guzzo, F.; Bagli, J. F.; McCaleb, M. L. Antihyperglycemic Activity of Novel Substituted 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1992, 35, 1176-1183. (b) Ellingboe, J. W.; Lombardo, L. J.; Alessi, T. R.; Nguyen, T. T.; Guzzo, F.; Guinosso, C. J.; Bullington, J.; Browne, E. N. C.; Bagli, J. F.; Wrenn, J.; Steiner, K.; McCaleb, M. L. Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1993, 36, 2485-2493. (c) Kees, K. L. U.S. Pat. 5,183,825. (d) Kees, K. L. U.S. Pat. 5,264,451. (e) Kees, K. L. U.S. Pat. 5,274,111.
32. Other heterocyclic replacements have been used; however, it is not clear whether the compounds are mechanistically equivalent to ciglitazone: (a) Ellingboe, J. W.; Alessi, T. R.; Dolak, T. M.; Nguyen, T. T.; Tomer, J. D.; Guzzo, F.; Bagli, J. F.; McCaleb, M. L. Antihyperglycemic Activity of Novel Substituted 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1992, 35, 1176-1183. (b) Ellingboe, J. W.; Lombardo, L. J.; Alessi, T. R.; Nguyen, T. T.; Guzzo, F.; Guinosso, C. J.; Bullington, J.; Browne, E. N. C.; Bagli, J. F.; Wrenn, J.; Steiner, K.; McCaleb, M. L. Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole-2-Oxides. J. Med. Chem. 1993, 36, 2485-2493. (c) Kees, K. L. U.S. Pat. 5,183,825. (d) Kees, K. L. U.S. Pat. 5,264,451. (e) Kees, K. L. U.S. Pat. 5,274,111.
33. (a) Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones as Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
34. (b) Stevenson, R. W.; Hutson, N. J.; Krupp, M. N.; Volkmann, R. A.; Holland, G. F.; Eggler, J. F.; Clark, D. A.; McPherson, R. K.; Hall, K. L.; Danbury, B. H.; Gibbs, E. M.; Kreutter, D. K. Diabetes 1990, 39, 1218.
35. Sohda, T.; Mizuno, K.; Kawamatsu, Y. Studies on Antidiabetic Agents. VI. Asymmetric transformation of (+)-5-[4-(1-Methyl-cyclohexylmethoxy)benzyl]2,4-thiazolidinedione (Ciglitazone) with Optically Active 1-Phenethylamines. Chem. Pharm. Bull. 1984, 32, 4460-4465.
36. Knihinicki, R. D.; Williams, K. M.; Day, R. O. Chiral Inversion of 2-Arylpropionic Acid Non-Steroidal Anti-Inflammatory Drugs - 1. In Vitro Studies of Ibuprofen and Flurbiprofen. Biochem. Pharmacol. 1989, 38, 4389-4395.
37. Damani, L. A. Metabolism of Sulfur-Containing Drugs. In Drug Metabolism - from Molecules to Man; Benford, D. J., Bridges, J. W., Gibson, G. G., Eds.; Taylor & Francis: London, U.K., 1987; pp 581-603.
38. Maximum stimulation was observed after 48 h in a time-course assay (data not shown).
39. Kreutter, D. K.; Andrews, K. M.; Gibbs, E. M.; Hutson, N. J.; Stevenson, R. W. Insulinlike Activity of New Antidiabetic Agent CP 68722 in 3T3-L1 adipocytes. Diabetes 1990, 39, 1414-1419.
40. 50's is therefore a lower limit.
41. (a) Rondestvedt, C. S., Jr. Arylation of Unsaturated Compounds by Diazonium Salts (the Meerwein Arylation Reaction). Org. React. 1976, 24, 225-259.
42. (b) Oae, S.; Shinhama, K.; Kim, Y. H. Direct Conversion of Arylamines to the Halides by Deamination with Thionitrite or Related Compounds and Anhydrous Copper (II) Halides. Bull. Chem. Soc. Jpn. 1980, 53, 1065-1069.
43. Helmchen, G.; Nill, G.; Flockerzi, D.; Youssef, M. S. K. Preparative Scale Directed Resolution of Enantiomeric Carboxylic Acids and Lactones via Liquid Chromatography and Neighboring-Group Assisted Hydrolysis of Diastereomeric Amides. Angew. Chem., Int. Ed. Engl. 1979, 18, 63-65.
44. (a) Evans, D. A.; Bartroli, J.; Shih, T. L. Enantioselective Aldol Condensations. 2. Erythro-Selective Chiral Aldol Condensations via Boron Enolates. J. Am. Chem. Soc. 1981, 103, 2127-2129.
45. For a review, see: (b) Evans, D. A. Studies in Asymmetric Synthesis. The Development of Practical Chiral Enolate Synthons. Aldrichima Acta 1982, 15, 23-32. (c) Gage, J. R.; Evans, D. A. Diastereoselective Aldol Condensation Using a Chiral Oxazolidinedione Auxiliary: (2S*,3S*)-3-Hydroxy-3-Phenyl-2-Methylpropanoic Acid. Organic Syntheses; Wiley: New York, 1980; Collect. Vol. VIII, pp 339-343.
46. For a review, see: (b) Evans, D. A. Studies in Asymmetric Synthesis. The Development of Practical Chiral Enolate Synthons. Aldrichima Acta 1982, 15, 23-32. (c) Gage, J. R.; Evans, D. A. Diastereoselective Aldol Condensation Using a Chiral Oxazolidinedione Auxiliary: (2S*,3S*)-3-Hydroxy-3-Phenyl-2-Methylpropanoic Acid. Organic Syntheses; Wiley: New York, 1980; Collect. Vol. VIII, pp 339-343.
47. For the Evans' aldol reaction of an α-alkoxy carboximide, see: (c) Evans, D. A.; Bender, S. L. Total Synthesis of the Ionophore Antibiotic X-206. Studies Relevant to the Stereoselective Synthesis of the C(17)-C(26) Synthon. Tetrahedron Lett. 1986, 27, 799-802.
48. A registered trademark of Abbott Laboratories, Diagnostic Division, 820 Mission St., So. Pasadena, CA 91030.
49. A modification of the method of Richterich and Dauwalder: Richterich, R.; Dauwalder, H. Assay of Blood-Glucose by Hexokinase/Glucose-6-Phosphate Dehydrogenase Method. Schweiz. Med. Wochenschr. 1971, 101, 615.
50. Sofia, M. J.; Chrakravarty, P. K.; Katzellenenbogen, J. A. Synthesis of Five-Membered Halo Enol Lactone Analogues of α-Amino Acids: Potential Protease Suicide Substrates J. Org. Chem. 1983, 48, 3318-3325.
51. Meguro, K.; Fujita, T. U.S. Patent 4,775,687.